BALTIMORE, July 6, 2011 /PRNewswire/ — Lupin Pharmaceuticals,
Inc. (LPI) announced today that the U.S. Food and Drug
Administration (US FDA) has granted final approval for its
Amlodipine / Benazepril 5mg/40mg, and 10mg/40mg capsules.
Commercial shipments of the product have already commenced.
This approval completes the product line as the Company was
granted final approval for Amlodipine / Benazepril 2.5mg/10mg,
5mg/10mg, 5mg/20mg and 10mg/20mg capsules in February 2010.
Lupin’s Amlodipine / Benazepril capsules are the AB-rated
generic equivalent of Novartis’ *Lotrel® capsules indicated for
the treatment of hypertension. Amlodipine / Benazepril
5mg/40mg, and 10mg/40mg capsules had annual sales of approximately
$290 million for the twelve months ended March 2011, based on IMS
Health sales data.
Headquartered in Mumbai, India, Lupin Limited is an innovation
led transnational pharmaceutical company producing a wide range of
quality, affordable generic and branded formulations and APIs. The
Company today has significant market share in Cardiovascular (prils
and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs in addition holding global leadership
positions in the Anti-TB and Cephalosporins space.
Today, Lupin is the 5th largest and fastest growing Top 5
generics player in the US (by prescriptions), the only Asian
company to achieve that distinction. The company is also the
fastest growing top 10 pharmaceutical players in India, Japan and
South Africa. (IMS)
For the financial year ended March 2011, Lupin’s Consolidated
Revenues and Profit after Tax were Rs.57,068 million and Rs. 8,626
million respectively. Please visit http://www.lupinworld.com for
more information about Lupin Ltd.
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary
of Lupin Limited. Headquarter